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ABSTRACT OF THE DISSERTATION 
THE EFFECT OF VITAMIN D3 SUPPLEMENTATION ON KIDNEY FUNCTION 
AND CARDIOVASCULAR DISEASE MARKERS AMONG HISPANICS AND 
AFRICAN AMERICANS WITH TYPE 2 DIABETES 
by 
Gustavo G. Zarini 
Florida International University, 2017 
Miami, Florida 
Professor Fatma G. Huffman, Major Professor 
Serum vitamin D deficiency/insufficiency, Chronic Kidney Disease (CKD) and 
elevated blood pressure are important health concerns especially among 
minorities with type 2 diabetes. The effect of vitamin D3 supplementation 
(cholecalciferol) at 6,000 IU/day (d) vs. 4,000 IU/d on kidney function and 
cardiovascular disease markers among Hispanics and African Americans with 
type 2 diabetes and hypovitaminosis D (<30 ng/ml) was evaluated. Subjects 
(n=63) were recruited from two clinics in Miami-Dade County, FL. Fasting venous 
blood and fresh, single-voided first morning urine samples were collected from 
each participant by a certified phlebotomist and analyzed by Solstas Lab 
Partners, Davie, FL. Linear mixed models were used to compare the interaction 
between time and intervention. Least Significant Difference (LSD) comparisons 
were used to detect significant differences within and between 4,000 IU/d and 
6,000 IU/d groups from baseline, 3 and 6 months. In the 4,000 IU/d and 6,000 
IU/d groups, a significant increase in serum 25-hydroxy vitamin D [25(OH)D] 
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levels were observed from baseline [(19.9±1.1 ng/mL) and (21.4±1.3 ng/mL)] to 3 
months [(36.1±2.2 ng/mL, p<.001) and (43.0±2.7 ng/mL, p<0.001)]; and 6 
months [(37.1±2.4 ng/mL, p<0.001) and (39.2±3.0 ng/mL, p<0.001)], 
respectively. Significant increase in estimated Glomerular Filtration Rate (eGFR) 
creatinine equation values were observed from baseline (81.2±3.0 mL/min) to 6 
months (90.2±2.8 mL/min, p<0.001) in the 4,000 IU/d group. Significant decrease 
in eGFR creatinine - cystatin C equation values were found from 3 months 
(109.2±3.9 mL/min) to 6 months (100.9±3.7 mL/min, p=0.006) in the 4,000 IU/d 
group. Systolic blood pressure levels significantly decreased from baseline 
(144.1±4.0 mmHg) to 6 months (134.5±3.5 mmHg, p=0.020) only for the 6,000 
IU/d group. Supplementation with vitamin D3 longer than 6 months may be 
needed to determine sustained long term effects in kidney and cardiovascular 
disease markers. Further research could provide more information for translation 
of these findings into recommendations for individuals with CKD, hypertension 
and type 2 diabetes. The efficacy of vitamin D3 supplementation as 
complementary therapy for CKD and blood pressure in minority and other ethnic 
groups needs further investigation in larger and longer duration randomized 
controlled trials. 
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CHAPTER I: INTRODUCTION 
Kidney Disease  
Kidney disease is the ninth leading cause of death in the U.S. (National 
Center for Health Statistics, 2012) affecting 31 million (10%) of American adults 
with the majority unaware of their conditions (CDC, 2011). Diabetes accounted 
for 44% of the incidence of kidney failure in 2012 (American Kidney Fund, 2015). 
Furthermore, complications from kidney disease are more prevalent in minorities: 
End Stage Renal Disease (ESRD) was nearly 1.5 times more likely in Hispanics 
as compared to non-Hispanic Whites (CDC, 2012). 
 
The Kidney Disease Improving Global Outcomes (KDIGO) guidelines 
(KDIGO, 2013) recommends using the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation with serum creatinine for initial evaluation and 
staging of kidney disease. The Modification of Diet in Renal Disease (MDRD) 
equation may not be as reliable as the CKD-EPI equation for Glomerular 
Filtration Rate (GFR) levels between 60 and 90 mL/min/1.73m2 (Levey et al., 
2009). Although the CKD-EPI equation (eGFR creatinine) adjust for age, gender 
and race, serum creatinine is affected by variations in diet and lean muscle mass 
(National Kidney Foundation, 2009). Cystatin C, a 13-kDa, single-chain amino 
acid present in almost all nucleated cells (Abrahamson et al., 1990), has been 
proposed as a confirmatory marker to add to the CKD-EPI equation, alone 
(eGFR cystatin) or with serum creatinine (eGFR creatinine- cystatin C), when 
eGFR creatinine is assumed inaccurate (KDIGO, 2013).  
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Microalbuminuria is considered an early biomarker for loss of kidney function. 
Microalbuminuria a sensitive marker recommended by the Kidney Disease 
Outcomes Quality Initiative (KDOQI) Clinical Practice guidelines to be used to 
assess and monitor kidney function in early stages of kidney disease (KDOQI, 
2000). Reported in previous studies, microalbuminuria was associated with 
cardiovascular disease and mortality in individuals with type 2 diabetes 
(Mogensen, 1984; Valmadrid et al., 2000). The American Diabetes Association 
recommends that individuals with type 2 diabetes be tested for microalbuminuria 
at the diagnosis of diabetes and subsequently every year (American Diabetes 
Association, 2009). Decrease in microalbuminuria values represents an 
improvement in kidney function and possible reduction in cardiovascular disease 
risk (KDOQI, 2000).  
 
Kidney Disease and Vitamin D 
The prevalence of chronic kidney disease (CKD) and hypovitaminosis D 
disproportionately affects minorities and individuals with type 2 diabetes (Diaz et 
al., 2009; Melamed et al., 2009; Zadshir et al., 2005). Data from the National 
Health and Nutrition Examination Survey (NHANES) indicated that cases of 
kidney disease were distributed disproportionally among Hispanics, with 
Hispanics presenting the highest proportion of kidney disease (38.5%), followed 
by non-Hispanic Blacks (36.2 %) and non-Hispanic Whites (27.8%) (Diaz et al., 
2009). Vitamin D status differ across ethnic groups. Non-Hispanic Blacks and 
Hispanics have higher rates (80.4% and 59.0%) of serum 25-hydroxy vitamin D 
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[25(OH)D] levels considered deficient as compared to Whites (39.5%, p<0.01) 
(Diaz et al., 2009). Individuals with kidney disease had higher rates of serum 
vitamin D deficiency (53.2%) as compared to those with normal kidney function 
(47.0%) (Diaz et al., 2009). Individuals with kidney disease were shown to have 
hypovitaminosis D even in the early stages of kidney disease (Lee et al., 2010). 
Moreover, since their kidneys are deteriorated, the ability to activate adequate 
amounts of vitamin D decline. Reduction in renal function over a 4-year period 
was greater for individuals with insufficient serum 25(OH)D and diabetes in 
Caucasian adults as compared to controls (de Boer et al., 2011). In a 5-year 
follow-up study of a random sample of Caucasians (n=4,330), aged 30-60 years, 
low 25(OH)D levels predicted higher protein excretion (Skaaby et al., 2013). 
Serum 25(OH)D levels have been inversely associated with albuminuria in a U.S. 
representative population and this association remained after controlling for 
diabetes (de Boer et al., 2007).   
 
Insufficient dietary and serum 25(OH)D levels could contribute to morbidity 
and mortality (Heaney et al., 2005; Zimmermann & Gummert, 2010). In the 
longitudinal study by Pilz et al. (2011), with a median follow-up time of 9.4 years, 
the risk of mortality in 444 individuals with CKD (stages 3-5) was higher in those 
with serum vitamin D deficiency as compared to those with normal vitamin D 
status (hazard ratios: 4.38, 95% CI 2.13–9.00). The mechanism that could 
explain the association between vitamin D status and mortality; however, 
remains unknown. Sufficient levels of serum 25(OH)D are protective of the renal 
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and cardiovascular systems; conversely, hypovitaminosis D may accelerate 
disease progression (Judd and Tangpricha, 2008; Li, 2012).  
 
Kidney Disease and Vitamin D Supplementation  
Supplementation that raises serum 25(OH)D levels has been recommended 
to prevent health problems in adults (Heaney et al., 2005; Williams, et al., 2009). 
Investigations of the effect of vitamin D3 supplementation on minorities with type 
2 diabetes; however, have been limited. Most vitamin D supplementation trials in 
patients with kidney disease have been conducted primarily in Caucasians 
without diabetes. Vitamin D3 supplementation at high doses [>2000 IU/day (d)] 
has promise for achieving vitamin D sufficiency for persons with CKD (Alvarez et 
al., 2012). On the other hand, studies concerning vitamin D2 supplementation 
and vitamin D status in kidney disease were less conclusive (Alvarez et al., 
2012). Vitamin D3 may provide a safer and more cost-effective strategy for the 
treatment of early CKD than oral vitamin D2 or synthetic analogues. There are 
some studies available on vitamin D3 supplementation in adults, in which kidney 
function was measured (Kim et al., 2011; Rucker et al., 2009; Molina et al., 
2014). Vitamin D3 supplementation, provided according to the participant’s 
vitamin D status, for 4 months showed a reduction of albuminuria, but no change 
in GFR for ethnically diverse (43% Caucasian, 22% Black, and 45% Asian) 
patients (n=63) with CKD stages 2-4 and hypovitaminosis D (Kim et al., 2011). 
Supplementation of 1000 IU/daily of vitamin D3 among 128 Canadian adults with 
later stages of kidney disease (stages 3-5) found no improvements in kidney 
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function (GFR) compared with a control group; however, supplementation was of 
short duration (3 months) and mean 25(OH)D levels were below vitamin D 
sufficiency (30 ng/mL) by the end of the study (Rucker et al., 2009). 
Supplementation of vitamin D3 at 666 IU/d for 6 months significantly lowered 
albuminuria in a Caucasian older adult cohort (n= 101) with CKD stages 3-4, but 
no significant improvements were found for estimated GFR (Molina et al., 2014). 
Early supplementation with vitamin D3 might provide a more valuable treatment 
and possibly delay adverse kidney disease outcomes.  
 
Blood Pressure and Vitamin D  
The Centers for Disease Control and Prevention (CDC) indicated that one in 
3 individuals living in the U.S., an estimated 70 million adults, have high blood 
pressure (CDC, 2015) which place them at higher risk to die from heart disease 
(Nwankwo et al., 2013). The CDC recommended decreasing individual’s systolic 
blood pressure by 12 to 13 mmHg because it could potentially reduce deaths 
from cardiovascular disease by 25%. Still, high levels of blood pressure among 
Hispanics and Blacks continue to be a challenge (CDC, 2013). 
 
Serum vitamin D deficiency/insufficiency and elevated blood pressure are 
important health concerns especially among minorities. Available evidence from 
observational studies indicated that low 25(OH)D levels are related to elevated 
blood pressure. A study by Schmitz et al. (2009) conducted in Hispanics and 
African Americans (n=1334) found an inverse association between 25(OH)D 
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levels and blood pressure, after adjusting for age, gender, ethnicity and seasons. 
When BMI was included in the final model, blood pressure was no longer 
associated with 25(OH)D levels. In this study, only a small proportion of subjects 
had systolic blood pressure ≥ 140 mmHg (n=72; 5%) and diastolic blood 
pressure ≥ 90 mmHg (n=93; 7%). Data from NHANES that included 12,644 
individuals ≥ 20 years old showed that after adjusting for age, gender, ethnic 
background, and physical activity, 25(OH)D levels were inversely linked with 
blood pressure (Scragg et al., 2007). When the highest quintile of 25(OH)D (≥ 87 
nmol/L) was compared to the lowest quintile (40.4 nmol/L), both mean systolic 
blood pressure and diastolic blood pressure were 3.0 mmHg and 1.6 mmHg 
lower in those in the highest quintile (Scragg et al., 2007). As in the study by 
Schmitz et al. (2009), addition of BMI as an adjustment variable in the model 
weakened the relationship between 25(OH)D and blood pressure levels. In the 
study by Scragg et al. (2007), systolic blood pressure continued to be significant 
despite adjustment. Likewise, Forman et al. (2007) found an inverse association 
between 25(OH)D and incident risk of hypertension by exploring two cohorts 
(men=613) from the Health Professionals’ Follow-up Study and Nurses’ Health 
Study (women=1198) ages 40-75.  
 
In contrast with the findings from observational studies, the relationship 
between vitamin D3 supplementation and its effect on blood pressure is not as 
clear. Clinical trials and meta-analyses have tried to elucidate the relationship 
between vitamin D supplementation and blood pressure; however, findings from 
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these studies are inconsistent. Results from some clinical trials and meta-
analysis were not able to determine significant reductions in blood pressure 
levels (Pittas et al., 2010; Witham et al., 2009; Jorde et al., 2010; Beveridge et 
al., 2015; Larsen et al., 2012) while other investigations did find significant 
improvements in blood pressure (Witham et al., 2010; Forman et al., 2013; 
Pfeifer et al., 2001; Sugden et al., 2008). The mechanism of how vitamin D 
affects blood pressure is poorly understood. Nonetheless, it has been postulated 
that vitamin D could affect blood pressure regulation through the Renin-
Angiotensin-Aldosterone System (RAAS) (Li et al., 2004; Pilz et al., 2009).  
 
Deficient/insufficient 25(OH)D levels could be corrected by vitamin D3 
supplementation which may be of significance and have a potential impact on 
health of minority groups with type 2 diabetes. Furthermore, improving blood 
pressure levels using vitamin D3 may prevent future complications associated 
with kidney and cardiovascular disease. The clinical importance of vitamin D3 
supplementation as adjunct therapy is to prevent kidney and cardiovascular 
disease complications.  
 
Significance of the Study 
Even though hypovitaminosis D, type 2 diabetes, kidney disease and 
cardiovascular disease are major health problems affecting minorities, no study 
so far has investigated the effect of two high doses of vitamin D3 
supplementation (4,000 IU/d and 6,000 IU/d) exclusively among Hispanics and 
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African Americans with type 2 diabetes and hypovitaminosis D. Supplementation 
with vitamin D3 may have the potential of delaying and managing the progression 
of CKD and cardiovascular disease. As an inexpensive and safe supplement, 
vitamin D3 (cholecalciferol) could have significant benefit in reducing diabetes 
complications and health disparities among Hispanics and African Americans 
with type 2 diabetes.  
 
Aims and Hypotheses 
Aim 1: To evaluate the effect of vitamin D3 supplementation (cholecalciferol) at 
6,000 IU/d vs. 4,000 IU/d on kidney function among Hispanics and African 
Americans with type 2 diabetes and hypovitaminosis D (<30 ng/ml). 
Hypothesis 1: Vitamin D3 supplementation at 6,000 IU/d will be more effective in 
raising 25-hydroxy vitamin D [25(OH)D] levels from deficient/insufficient to 
sufficient as compared to 4,000 IU/d over 6 months. 
Hypothesis 2: Vitamin D3 supplementation at 6,000 IU/d will be more effective in 
increasing estimated glomerular filtration rate (eGFR) using CKD-EPI creatinine 
equation (Chronic Kidney Disease Epidemiology Collaboration) when compared 
to 4,000 IU/d over 6 months. 
Hypothesis 3: Vitamin D3 supplementation at 6,000 IU/d will be more effective in 
increasing eGFR using CKD-EPI creatinine - cystatin C equation (Chronic Kidney 
Disease Epidemiology Collaboration) when compared to 4,000 IU/d over 6 
months. 
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Hypothesis 4: Vitamin D3 supplementation at 6,000 IU/d will be more effective 
than the 4,000 IU/d over 6 months in lowering microalbuminuria measured by 
first morning urine samples.  
 
Aim 2: To evaluate the effect of vitamin D3 supplementation at 6,000 IU/d vs. 
4,000 IU/d on markers of cardiovascular disease risk among Hispanics and 
African Americans with type 2 diabetes and hypovitaminosis D (<30 ng/ml).  
Hypothesis 1: Vitamin D3 supplementation at 6,000 IU/d will be more effective 
than the 4,000 IU/d over 6 months in lowering systolic and diastolic blood 
pressure levels.  
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Table 1: Summary of Aims, Hypotheses and Statistical Analyses 
Aims Hypotheses 
Dependent & 
Independent 
Variables 
Controlled 
Variables 
Statistical 
Analysis 
Aim 1: To evaluate the 
effect of vitamin D3 
supplementation 
(cholecalciferol) at 
6,000 IU/d vs. 4,000 
IU/d on kidney function 
among Hispanics and 
African Americans with 
type 2 diabetes and 
hypovitaminosis D 
(<30 ng/ml). 
 
Hypothesis 1: Vitamin D3 
supplementation at 6,000 IU/d 
will be more effective in raising 
25-hydroxy vitamin D 
[25(OH)D] levels from 
deficient/insufficient to 
sufficient as compared to 
4,000 IU/d over 6 months. 
H1 –  
DV: DV: 
25(OH)D 
IV: vitamin D3 
supplementation 
Age gender, 
BMI, known 
years with 
diabetes, A1c, 
diabetes 
medications, 
blood pressure 
medications, 
vitamin D 
intake, sun 
exposure. 
All data analyses 
for the study was 
conducted on an 
“intent to treat” 
basis. Normal 
distribution of all 
variables was 
assessed. 
Independent t-
test (parametric) 
or Mann-Whitney 
U-test 
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 Hypothesis 2: Vitamin D3 
supplementation at 6,000 IU/d 
will be more effective in 
increasing eGFR using CKD-
EPI creatinine equation 
(Chronic Kidney Disease 
Epidemiology Collaboration) 
when compared to 4,000 IU/d 
over 6 months. 
H2 –  
DV: eGFR 
creatinine 
IV: vitamin D3 
supplementation 
BMI, known 
years with 
diabetes, A1c, 
diabetes 
medications, 
blood pressure 
medications, 
25(OH)D, 
vitamin D 
intake, sun 
exposure. 
(nonparametric) 
for continuous 
variables and chi-
square test for 
categorical 
variables were 
used to compare 
differences in 
baseline 
characteristics of 
participants 
across the two 
intervention 
groups. For aims 
1 and 2, mixed 
models were 
Hypothesis 3: Vitamin D3 
supplementation at 6,000 IU/d 
will be more effective in 
increasing estimated 
glomerular filtration rate 
H3 –  
DV: eGFR 
creatinine – 
cystatin C 
IV: vitamin D3 
BMI, known 
years with 
diabetes, A1c, 
diabetes 
medications, 
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(eGFR) using CKD-EPI 
creatinine - cystatin C equation 
(Chronic Kidney Disease 
Epidemiology Collaboration) 
when compared to 4,000 IU/d 
over 6 months. 
supplementation blood pressure 
medications, 
25(OH)D, 
vitamin D 
intake, sun 
exposure. 
performed using 
estimated 
glomerular 
filtration (eGFR) 
rates, 
microalbuminuria, 
systolic and 
diastolic blood 
pressure levels 
as the dependent 
variable, 
respectively. The 
interaction 
between time 
and intervention 
were included to 
Hypothesis 4: Vitamin D3 
supplementation at 6,000 IU/d 
will be more effective than the 
4,000 IU/d over 6 months in 
lowering microalbuminuria 
measured by first morning 
urine samples. 
H4 –  
DV: MAU 
IV: vitamin D3 
supplementation 
Age gender, 
BMI, known 
years with 
diabetes, A1c, 
diabetes 
medications, 
blood pressure 
medications, 
25(OH)D, 
vitamin D 
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intake, sun 
exposure. 
evaluate the 
dosage effect on 
the change of the 
dependent 
variable over 
time. 
Aim 2: To evaluate the 
effect of vitamin D3 
supplementation at 
6,000 IU vs. 4,000 IU/d 
on markers of 
cardiovascular disease 
among Hispanics and 
African Americans with 
type 2 diabetes and 
hypovitaminosis D 
(<30 ng/ml). 
Hypothesis 1: Vitamin D3 
supplementation at 6,000 IU/d 
will be more effective than the 
4,000 IU/d over 6 months in 
lowering systolic and diastolic 
blood pressure levels.  
 
 
H1 –  
DV: SBP & DBP 
IV: vitamin D3 
supplementation 
Age gender, 
BMI, known 
years with 
diabetes, A1c, 
diabetes 
medications, 
blood pressure 
medications, 
25(OH)D, 
vitamin D 
intake, sun 
exposure. 
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CHAPTER II: METHODS 
The clinical trial conducted by our laboratory entitled “The effect of vitamin D 
supplementation on cardiovascular risk factors among Hispanics and African 
Americans with type 2 diabetes” was approved by the Institutional Review Board 
(IRB) at Florida International University (IRB Protocol Approval #: IRB-13-0155). 
 
Recruitment of Subjects 
Subjects were recruited from two clinics in Miami-Dade County, Florida 
(Borinquen Health Care Center and Clinical Care Medical Center) from July 2011 
to March 2013 using flyers explaining the purpose of the study, 
inclusion/exclusion criteria and containing investigators’ emails and phone 
numbers. The non-randomized study screened subjects based on the inclusion/ 
exclusion criteria described as follows:  
Inclusion criteria:  
▪ Serum vitamin D insufficiency [25(OH)D< 30 ng/ml];  
▪ Age 30-70 years old;  
▪ Hispanic or African American; and  
▪ Having type 2 diabetes 
 Exclusion criteria:  
▪ Taking vitamin D supplements other than standard multivitamin formula;  
▪ Pregnant or lactating;  
▪ Kidney disease (glomerular filtration rate lower than 30 ml/min/1.73m2, 
stages 4-5) and kidney failure (defined as currently on dialysis).   
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▪ Using insulin to manage blood glucose; 
▪ Major psychiatric disorders; 
▪ Cancer;  
▪ HIV/AIDS; and 
▪ Hepatitis  
 
Enrollment and Intervention 
All subjects signed an informed consent in Spanish or English based on their 
preference prior to participation in the study. Participants in both intervention 
groups were required to take either 4,000 IU or 6,000 IU of vitamin D3 given in 
the form of a pill in a single daily dose. Subjects in the 4,000 IU/d group were 
recruited first and intervention was provided. Subjects were included on a first 
come, first served basis until the required calculated sample size was attained. 
After recruitment for the 4,000 IU/d group was completed, we conducted the 
recruitment for the 6,000 IU/d group. Hence, group selection was not conducted 
randomly and did not run in parallel. The number of subjects in the 6,000 IU/d 
group was reduced to the minimum sample size required to find significant 
differences in the main outcome variables.  
 
Ninety-two participants were screened [4,000 IU/d group (n= 63) and 6,000 
IU/d group (n= 29)]. Sixty-three qualified for the study and were enrolled for the 
vitamin D3 intervention [4,000 IU/d group (n=39) and (6,000 IU/d (n=24)]. Four 
participants were lost to follow-up after baseline [4,000 IU/d group (n=1) and 
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6,000 IU/d group (n=3)]. Additionally, two participants were lost to follow-up after 
the 3 months’ assessment in the 6,000 IU/d group (Figure 1). Participants CKD 
stages at baseline: (n=45, 71.0%) CKD stage 1 (≥ 90 eGFR ml/min/1.73 m2); 
(n=15, 24%) CKD stage 2 (60-89 eGFR ml/min/1.73 m2); (n=3, 5.0%) CKD stage 
3 (30-59 eGFR ml/min/1.73 m2). The study used an intent to treat approach, all 
63 subjects were included in the statistical analysis. Each participant was seen 4 
times during the study (screening, baseline, 3 and 6 months). Table 1 describes 
assessments and assays conducted at each visit.  
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Figure 1. Flow Diagram Showing Recruitment and Follow-Up of Participants 
 
 
 
 
 
 
 
 
 
 
Abbreviations: AA= African Americans; H= Hispanics.  
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Table 1. Assessments Frequency  
Abbreviations: 25(OH)D= 25-hydroxy vitamin D, PTH= parathyroid hormone, hs-CRP= 
High-sensitivity C-reactive Protein, A1C= hemoglobin A1c, FFQ= food frequency 
questionnaire, (S)=screening, (B)=baseline. 
 
Safety of the Intervention and Monitoring 
Participants were monitored monthly for any symptoms of vitamin D3 toxicity 
(nausea, vomiting, polyuria, polydipsia, weakness, nervousness, etc.) by 
telephone, and at each follow-up visit that measured serum 25(OH)D levels. 
Study adherence and compliance was assessed using serum 25(OH)D and PTH 
levels change, pill count and attendance of scheduled visits at the clinics. 
Compliance to the vitamin D3 supplementation was defined as taken more than 
80% of the pills. To facilitate reporting to the clinics at data collection times, a 
modest compensation for time and travel and laboratory reports were provided. A 
Data Safety Monitoring Board (DSMB) monitored the safety of vitamin D3 
supplementation every 12 month intervals for two years. This included evaluation 
Activity S B 3 6 
Blood collection and analysis: serum 25(OH)D, PTH, creatinine, 
cystatin C, hs-CRP, FPG and A1c 
X  X X 
Urine: albumin and creatinine X  X X 
Anthropometrics: height, weight and BMI  X  X X 
Demographics, FFQ & blood pressure X X X X 
Sun Exposure: (Skin Color - reflectance colorimetry using the IMS 
SmartProbe 400) 
X X X X 
Determine medications for diabetes and hypertension and monitor 
medication changes 
X X X X 
Study adherence/compliance: pill count and compliance  X X X 
Monitor safety and toxicity  X X X 
Vitamin D3 (cholecalciferol) supplements distribution  X X  
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of participant’s enrollment, follow-up visits, compliance, laboratory results, and 
data management.  
 
Vitamin D3 Supplements 
Vitamin D3 (cholecalciferol) supplements at 4,000 IU and 6,000 IU were 
custom manufactured by Biotech Pharmacal, Inc. (Fayetteville, AZ, U.S.) in a 
single batch for each strength to avoid variation between lots. Since there was a 
three-year expiration date, participants received the same 4,000 IU or 6,000 IU 
lots accordingly. A certificate of Analysis was provided by the manufacturer to 
assure that the product meets research specifications.   
 
Blood Collection 
Fasting venous blood (20 ml) was collected from each participant by a 
certified phlebotomist using standard laboratory methods. After coagulation, 
blood was centrifuged at 2500 RPM for 30 minutes. Solstas Lab Partners, Davie, 
FL, U.S. performed blood and urine analyses using the standard procedures as 
outlined. 
 
Serum 25(OH)D levels were measured with an enzyme-immunoassay kit by 
absorbance (Immunodiagnostic Systems; Scottsdale, AZ, U.S.), where the color 
intensity is proportional to the concentration of 25(OH)D. 
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Parathyroid Hormone was tested by a two-sided ELISA (Enzyme-Linked 
ImmonoSorbent Assay) for the measurement of the biologically active 84 amino 
acid chain of PTH. 
 
Hemoglobin A1c was measured from whole blood samples using the Roche 
Tina Quant methods and fasting plasma glucose was measured by hexokinase 
enzymatic methods by Solstas Lab Partners, Davie, FL, U.S. 
 
Creatinine (Serum) was measured using the Roche enzymatic method (Roche-
Hitachi P-Module instrument with Roche Creatininase Plus assay, Roche Applied 
Science, IN, U.S.). 
 
Cystatin C (Serum) was measured in serum using an enzyme-linked 
immunosorbent assay (ELISA) method (BioVendor LLC, NC, U.S.). 
 
High Sensitivity-CRP (hs-CRP) was analyzed by Immulite (Diagnostic Products 
Corporation, Los Angeles, CA). The Immulite assay is a 2-site chemiluminescent 
enzyme immunometric assay with one monoclonal and one polyclonal anti-CRP 
antibody. 
 
Urine Collection 
Fresh, single-voided, first morning urine samples were collected from each 
participant to determine the following biomarkers of kidney function. 
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Urinary Albumin: Albumin was determined by immunoturbidmetric assay using 
the Beckman Coulter microalbumin reagent with polyclonal antiserum. Turbidity 
was measured at 340nm and 700nm on a spectrophotometer and albumin was 
quantitatively determined using calibration curves. The immunoturbidometric 
assay has been established as high sensitivity and high selectivity method for 
detection of urinary albumin in normal and abnormal ranges for persons with 
diabetes. 
 
Creatinine (Urine): This procedure is a modification of the Jaffe method in which 
creatinine reacts with picric acid at alkaline pH to form a yellow orange complex. 
Color intensity is measured against a standard curve. 
 
Estimation of Glomerular Filtration Rate (GFR) 
Glomerular Filtration Rate equations were calculated using the online calculator 
from the National Kidney Foundation 
http://www.kidney.org/professionals/KDOQI/gfr_calculator). The online calculator 
takes into consideration both serum creatinine and serum cystatin C 
concentrations (CKD-EPI creatinine and CKD-EPI creatinine - cystatin C) as well 
as age, gender, and race.  
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Sociodemographic Data were collected with trained, bilingual interviewers 
(English/ Spanish). Subjects were asked to complete a sociodemographic 
questionnaire which included questions related to gender, age, education, 
income, employment status, health insurance, smoking, and medications.  
 
Vitamin D Intake 
A short food frequency questionnaire containing 22 foods and beverages 
designed to assess vitamin D and calcium intake was administered. The 
questionnaire included participants’ frequency of consumption of each food and 
the serving size. Total vitamin D intake was calculated following the original 
rubric (Blalock et al., 2003). 
 
Anthropometric Measures 
Height and weight were measured using a Seca balance scale with 
stadiometer (Seca Corp, Columbia, MD, U.S.). Body mass index (BMI) was 
calculated as weight in kg/height in m2. Waist circumference to the nearest 0.1 
cm was measured horizontally with a non-stretchable measuring tape placed 
midway between the 12th rib and iliac crest at minimal respiration to determine 
central obesity (NHLBI, 1998). Each measurement was taken twice and 
averaged.  
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Sun Exposure – (Skin Color) 
Skin color was determined by reflectance colorimetry using the IMS 
SmartProbe 400, Milford, CT. The instrument uses the International Commission 
on Illumination Scale which ranges from 0 (black) to 100 (white) for skin color. 
Two readings for each participant were taken, one on the right-hand wrist (area 
most exposed to the sun) and other under the right upper arm (area least 
exposed to the sun). The differences between the two measures were 
determined to calculate the delta of skin color due to sun exposure. 
 
Statistical Analysis 
All data analyses were conducted on an “intent to treat” basis. Normal 
distribution of all continuous variables was assessed using Shapiro-Wilk test. 
Data was reported as means with standard deviation for continuous variables 
and count and percentages for categorical variables. Independent t-test 
(parametric) or Mann-Whitney U-test (non-parametric) for continuous variables 
and chi-square test for categorical variables were used to compare differences in 
baseline characteristics of participants across the two intervention groups (4,000 
IU/d vs. 6,000 IU/d). Paired t-test was used evaluated pre- and post-intervention 
(time effect) for normally distributed variables and Wilcoxon signed-rank test was 
used for non-normally distributed variables for each study group.  
 
Results from aims 1 and 2 were reported as mean with standard error. Linear 
mixed models were performed using, 25(OH)D levels, estimated glomerular 
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filtration rate (eGFR) equations, microalbuminuria, systolic and diastolic blood 
pressure levels as the dependent variables, respectively. The interaction 
between time and intervention was included to evaluate the dosage effect on the 
change of the dependent variables over time. Least Significant Difference (LSD) 
comparisons test were used to detect significant differences within and between 
4,000 IU/d and 6,000 IU/d groups from baseline, 3 and 6 months on the outcome 
variables without and with the adjustment of confounders. Linear mixed models 
included the adjustment variables that were major confounders of serum 
25(OH)D, kidney function and cardiovascular disease. Potential additional 
covariates were tested by correlation with the dependent variable. Adjustment 
variables included: age; gender; BMI; duration of diabetes; hemoglobin A1c; 
vitamin D intake; sun exposure; serum vitamin D; and medication(s) usage. 
Covariates that were related to outcomes were included as needed. The 
analyses were conducted using SPSS software (SPSS Inc., Chicago, IL, U.S.) 
version 23. All tests were analyzed two-sided and a significance level of <0.05 
was used to decide the statistical significance.  
 
Sample Size and Power Analysis 
A statistical power analysis was performed using PASS 15 (Power Analysis 
and Sample Size) 2017 Statistical Software (UT, U.S.) for Mixed Models, within-
between groups interaction. Given an alpha of 0.05, a sample size of n=63 (n=39 
for the group 4,000 IU/d and n=24 for the 6,000 IU/d) will have 82.0% power to 
detect difference in eGFR (CKD-EPI) creatinine from baseline to 6 months. Thus, 
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the sample size of n=63 was more than adequate for the main outcome of this 
study and allowed to adjust for possible confounding factors. Additionally, power 
analyses were calculated for other outcomes in the study (Table 2). 
 
Table 2. Outcomes Power Calculation 
 
 
 
 
 
 
 
 
Outcomes Power 
Sample 
Size 
Alpha 
25-hydroxy vitamin D 82.0% 57 0.05 
eGFR (CKD-EPI creatinine) 82.0% 57 0.05 
eGFR (CKD-EPI creatinine - cystatin C) 84.0% 57 0.05 
Microalbuminuria  70.0% 57 0.05 
Systolic Blood Pressure 84.0% 57 0.05 
Diastolic Blood Pressure 79.0% 57 0.05 
Abbreviations: eGFR= Estimated Glomerular Filtration Rate; CKD-EPI=Chronic 
Kidney Disease Epidemiology.  
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CHAPTER III: RESULTS 
Baseline Comparisons of Vitamin D3 Intervention Groups  
The participants in this study were 53.4±8.3 years old (4,000 IU/d group) and 
55.0±10.3 years old (6,000 IU/d group), the majority were female in both groups 
71.8% (4,000 IU/d group) and 58.3% (6,000 IU/d group) respectively. The mean 
known duration of diabetes was 6.1±4.7 years in the 4,000 IU/d group and 
6.8±6.4 years in the group receiving 6,000 IU/d, and BMI above 30 kg/m2 in both 
intervention groups classified them in the obesity category. All participants 
started the study with serum 25(OH)D levels considered as deficient/insufficient 
(20.7±6.0 ng/mL in the 4,000 IU/d group and 21.7±5.6 ng/mL in the 6,000 IU/d 
group). At baseline, participants at the 4,000 IU/d group had significantly lower 
systolic blood pressure levels (126.9±18.2 mmHg) and diastolic blood pressure 
levels (82.3±10.7 mmHg) as compared with those in the 6,000 IU/d group 
[(146.2±22.1 mmHg, p<.001) and (91.9±10.9 mmHg, p=0.001) respectively]. The 
4,000 IU/d group had lower percentage of smokers (7.7% vs. 25.0%, p=0.057) 
and higher serum creatinine levels (0.92±0.24 mg/dL vs. 0.80±0.20 mg/dL, 
p=0.066) as compare with the 6,000 IU/d group. Participants in the 4,000 IU/d 
group had significantly lower CKD-EPI creatinine values (84.6±18.4 mL/min) 
compared with those in the 6,000 IU/d group (94.2±17.5 mL/min, p=0.027) 
(Table 1).  
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Table 1. Baseline Comparisons of Vitamin D3 Intervention Groups 
 Intervention  
 4,000 IU/d 6,000 IU/d  
Variables n=39 n=24 P-Value 
Age (years) 53.4±8.3 55.0±10.3 0.499 
Sex (Female) n (%) 28(71.8) 14(58.3) 0.271 
BMI (kg/m2) 34.7±7.6 32.7±6.0 0.492 
Waist circumference (cm) 109.6±18.6 107.3±12.4 0.388 
Known years with diabetes 6.1±4.7 6.8±6.4 0.983 
Smoking (yes) n (%) 3(7.7) 6(25.0) 0.057 
Marital Status (married, yes) n (%) 22(56.4) 11(45.8) 0.862 
Employment (yes) n (%) 22(56.4) 15(62.5) 0.383 
Medical insurance (yes) n (%) 19(48.7) 11(45.8) 0.824 
Diabetes medications (yes) n (%) 36(92.3) 22(91.7) 0.927 
Blood pressure medications (yes) n (%) 26(66.7) 14(58.3) 0.505 
Systolic blood pressure (mmHg) 126.9±18.2 146.2±22.1 <0.001 
Diastolic blood pressure (mmHg) 82.3±10.7 91.9±10.9 0.001 
Blood Biomarkers     
   25(OH)D (ng/mL) 20.7±6.0 21.7±5.6 0.457 
   PTH (pmol/L) 39.4±19.5 42.6±16.5 0.322 
   Insulin (μU/mL) 14.1±14.1 11.5±7.2 0.697 
   FGP (mg/dL) 189.0±88.7 184.4±71.6 0.944 
   A1c (%) 8.4±2.3 8.8±2.2 0.282 
   Hs-CRP (mg/L) 9.7±13.4 5.7±4.0 0.860 
   Cystatin C (mg/L) 0.70±0.19 0.70±0.25 0.865 
   Serum creatinine (mg/dL) 0.92±0.24 0.80±0.20 0.066 
Urinary Biomarkers    
   Creatinine (mg/dL) 127.6±57.8 131.9±65.0 0.777 
   MAU (mg/dL) 4.5±15.2 6.9±15.1 0.152 
Estimated GFR Equations    
   CKD-EPI creatinine (mL/min) 84.6±18.4 94.2±17.5 0.027 
   CKD-EPI creatinine - cystatin C                      112.6±21.5 114.0±23.2 0.112 
   (mL/min)    
Sun exposure     
   Upper arm skin color  58.9±9.8 60.4±7.3 0.837 
   Forearm skin color  55.2±8.7 56.6±6.0 0.915 
   Delta of skin color 3.7±3.6 3.9±5.0 0.510 
Dietary     
   Vitamin D intake (IU/d) 127.0±82.7 122.2±86.4 0.692 
   Multivitamins (yes) n (%) 9(23.1) 5(20.8) 0.835 
   Alcohol intake n (%)   0.781 
      None  28(71.8) 18(75.0)  
      1 or more servings per week 11(28.2) 6(25.0)  
Abbreviations: BMI= body mass index; 25(OH)D=25-hydroxy vitamin D; 
PTH=parathyroid hormone; A1c=glycated hemoglobin; FPG=fasting plasma glucose; 
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MAU=microalbuminuria; GFR= Glomerular filtration rate; CKD-EPI=Chronic Kidney 
Disease Epidemiology Collaboration; d=day; SD= standard deviation. Data reported as 
Mean±SD; unless otherwise indicated. P is considered significant at <0.05.    
 
 
 
Paired Comparisons of Vitamin D3 at 4,000 IU from Pre- to Post- 
Intervention 
Findings from paired comparisons of vitamin D3 at 4,000 IU/d from pre- to post- 
interventions are shown in Table 2. Serum 25(OH)D levels significantly 
increased from baseline (20.7±6.0 ng/mL) to 6 months (37.9±13.2 ng/mL, 
p<0.001). Cystatin C levels were significantly different from baseline (0.70±0.19 
mg/L) to 6 months (0.79±0.28 mg/L, p=0.045). Serum creatinine levels 
significantly decreased from baseline (0.92±0.24 mg/dL) to 6 months (0.83±0.25 
mg/dL, p=0.001). CKD-EPI creatinine values significantly increased from 
baseline (84.6±18.4 mL/min) to 6 months (92.4±18.9 mL/min, p<0.001). On the 
other hand, CKD-EPI creatinine - cystatin C values significantly decreased from 
baseline (112.6±21.5 mL/min) to 6 months (98.6±24.0 mL/min, p=0.022) (Table 
2).    
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Table 2. Paired Comparisons of Vitamin D3 at 4,000 IU from Pre- to Post- 
Intervention 
Abbreviations: BMI= body mass index; 25(OH)D=25-hydroxy vitamin D; 
PTH=parathyroid hormone; A1c=glycated hemoglobin; FPG=fasting plasma glucose; 
MAU=microalbuminuria; GFR= Glomerular filtration rate; CKD-EPI=Chronic Kidney 
Disease Epidemiology Collaboration; d=day; SD= standard deviation. Data reported as 
Mean±SD; unless otherwise indicated. P is considered significant at <0.05.    
 
 
 
 
 
 Intervention (4,000 IU/d)   
 n=39  
Variables Baseline 6 months P-Value 
BMI (kg/m2) 34.7±7.6 35.4±7.5 0.136 
Waist circumference (cm) 109.6±18.6 109.0±17.8 0.913 
Systolic blood pressure (mmHg) 126.9±18.2 127.9±17.0 0.690 
Diastolic blood pressure (mmHg) 82.3±10.7 83.5±9.1 0.459 
Blood biomarkers     
   25(OH)D (ng/mL) 20.7±6.0 37.9±13.2 <0.001 
   PTH (pmol/L) 39.4±19.5 37.2±17.8 0.149 
   Insulin (μU/mL) 14.1±14.1 11.4±8.1 0.267 
   FGP (mg/dl) 189.0±88.7 170.1±73.6 0.133 
   A1c (%) 8.4±2.3 8.2±2.1 0.787 
   Hs-CRP (mg/L) 9.7±13.4 7.4±7.0 0.602 
   Cystatin C (mg/L) 0.70±0.19 0.79±0.28 0.045 
   Serum creatinine (mg/dL) 0.92±0.24 0.83±0.25 0.001 
Urinary biomarkers    
   Creatinine (mg/dL) 127.6±57.8 143.3±67.8 0.500 
   MAU (mg/dL) 4.5±15.2 3.4±9.0 0.816 
Estimated GFR Equations    
   CKD-EPI creatinine (mL/min) 84.6±18.4 92.4±18.9 <0.001 
   CKD-EPI creatinine - cystatin C  112.6±21.5 98.6±24.0 0.022 
   (mL/min)    
Sun exposure     
   Upper arm skin color  58.9±9.8 59.3±9.9 0.346 
   Forearm skin color  55.2±8.7 55.5±8.6 0.827 
   Delta of skin color 3.7±3.6 3.8±4.2 0.971 
Dietary     
   Vitamin D intake (IU/d) 127.0±82.7 132.8±90.4 0.913 
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Table 3 shows findings from paired comparisons of vitamin D3 at 6,000 IU/d 
from pre- to post- intervention. Systolic blood pressure levels (146.2±22.1 
mmHg) significantly decreased from baseline to 6 months (135.0±17.8 mmHg, 
p=0.009) and diastolic blood pressure marginally decreased (91.9±10.9 mmHg to 
87.9±10.7 mmHg, p=0.077). Serum 25(OH)D levels significantly increased from 
baseline (21.7±5.6 ng/mL) to 6 months (38.9±16.3 ng/mL, p<0.001). Serum 
creatinine levels significantly decreased from baseline (0.80±0.20 mg/dL) to 6 
months (0.74±0.20 mg/dL, p=0.004). CKD-EPI creatinine values significantly 
increased from baseline (94.2±17.5 mL/min) to 6 months (97.9±18.0 mL/min, 
p=0.047). There were marginally significant differences from baseline (56.6±6.0) 
to 6 months (57.0±6.6, p=0.077) in forearm sun exposure scores. 
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Table 3. Paired Comparisons of Vitamin D3 at 6,000 IU from Pre- to Post- 
Intervention 
Abbreviations: BMI= body mass index; 25(OH)D=25-hydroxy vitamin D; 
PTH=parathyroid hormone; A1c=glycated hemoglobin; FPG=fasting plasma glucose; 
MAU=microalbuminuria; GFR= Glomerular filtration rate; CKD-EPI=Chronic Kidney 
Disease Epidemiology Collaboration; d=day; SD= standard deviation. Data reported as 
Mean±SD; unless otherwise indicated. P is considered significant at <0.05.    
 
 
 
 
 
 
 Intervention (6,000 IU/d)   
 n=24  
Variables 
Baseline 6 months 
P-
Value 
BMI (kg/m2) 32.7±6.0 33.1±6.3 0.970 
Waist circumference (cm) 107.3±12.4 102.7±24.9 0.404 
Systolic blood pressure (mmHg) 146.2±22.1 135.0±17.8 0.009 
Diastolic blood pressure (mmHg) 91.9±10.9 87.9±10.7 0.077 
Blood biomarkers     
   25(OH)D (ng/mL) 21.7±5.6 38.9±16.3 <0.001 
   PTH (pmol/L) 42.6±16.5 38.3±17.3 0.052 
   Insulin (μU/mL) 11.5±7.2 11.4±7.1 0.577 
   FGP (mg/dl) 184.4±71.6 180.7±73.9 0.697 
   A1c (%) 8.8±2.2 8.6±2.0 0.139 
   Hs-CRP (mg/L) 5.7±4.0 7.4±7.1 0.270 
   Cystatin C (mg/L) 0.70±0.25 0.75±1.9 0.365 
   Serum creatinine (mg/dL) 0.80±0.20 0.74±0.20 0.004 
Urinary biomarkers    
   Creatinine (mg/dL) 131.9±65.0 117.1±48.4 0.306 
   MAU (mg/dL) 6.9±15.1 7.0±14.2 0.370 
Estimated GFR Equations    
   CKD-EPI creatinine (mL/min) 94.2±17.5 97.9±18.0 0.047 
   CKD-EPI creatinine - cystatin C  114.0±23.2 107.4±20.1 0.270 
   (mL/min)    
Sun exposure     
   Upper arm skin color  60.4±7.3 61.1±6.5 0.173 
   Forearm skin color  56.6±6.0 57.0±6.6 0.072 
   Delta of skin color 3.9±5.0 4.2±4.6 0.417 
Dietary     
   Vitamin D intake (IU/d) 122.2±86.4 115.9±82.9 0.638 
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Aim 1: To evaluate the effect of vitamin D3 supplementation (cholecalciferol) at 
6,000 IU/d vs. 4,000 IU/d on kidney function among Hispanics and African 
Americans with type 2 diabetes and hypovitaminosis D (<30 ng/ml). 
 
Hypothesis 1: Vitamin D3 supplementation at 6,000 IU/d will be more effective in 
raising 25(OH)D levels from deficient/insufficient to sufficient as compared to 
4,000 IU/d over 6 months. 
 
Unadjusted linear mixed models indicated statistically significant effect of 
time on serum 25(OH)D levels (p<0.001). However, the effect of intervention 
(p=0.294) and interaction between time and intervention (p=0.120) were not 
statistically significant. Post-hoc LSD analyses showed significant improvements 
in serum 25(OH)D levels over time in both intervention groups. In the 4,000 IU/d 
and 6,000 IU/d groups respectively, significant increase in serum 25(OH)D levels 
were observed from baseline [(20.7±0.9 ng/mL) and (21.7±1.2 ng/mL)] to 3 
months [(37.0±2.1 ng/mL, p<0.001) and (42.6±2.6 ng/mL, p<0.001)] and to 6 
months [(37.9±2.3 ng/mL, p<0.001) and (38.9±2.9 ng/mL, p<0.001)] respectively 
(Table 4). 
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Table 4. Unadjusted and Adjusted Intervention Groups Comparisons of 25(OH)D at Different Time Points 
 Intervention 
 4,000 IU/d 6,000 IU/d 
Unadjusted n=39 n=24 
25(OH)D (ng/mL) Mean±SE 
   Baseline 20.7±0.9 21.7±1.2 
   3 months  37.0±2.1*  42.6±2.6* 
   6 months  37.9±2.3*  38.9±2.9* 
P-value time=0.001 P-value intervention=0.294 P-value interaction=0.120 
Adjusted   
25(OH)D (ng/mL) Mean±SE 
   Baseline 19.8±1.1 21.4±1.2 
   3 months  36.1±2.2*      43.0±2.7*; ** 
   6 months  37.1±2.4*  39.2±3.0* 
P-value time=0.001 P-value intervention=0.143 P-value interaction=0.088 
Abbreviations: BMI= body mass index; 25(OH)D=25-hydroxy vitamin D; A1c=glycated hemoglobin; SE=standard error. 
*Represents significant differences from baseline; **represents significant differences from 3 to 6 months.  
Adjustment variables: age gender, BMI, known years with diabetes, A1c, diabetes medications, blood pressure 
medications, 25(OH)D, vitamin D intake, sun exposure. Data reported as Mean±SE. P is considered significant at <0.05.      
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Adjusted linear mixed models after including covariates in the analysis, a 
statistically significant effect of time on 25(OH)D levels (p<0.001) was observed. 
However, the effect of intervention between groups was not statistically 
significant (p<0.143). There was a marginally significant result for the interaction 
between time and intervention (p=0.088). In the 4,000 IU/d and 6,000 IU/d 
groups, a significant increase in serum 25(OH)D levels were observed from 
baseline [(19.9±1.1 ng/mL) and (21.4±1.3 ng/mL)] to 3 months [(36.1±2.2 ng/mL, 
p<.001) and (43.0±2.7 ng/mL, p<0.001)] and 6 months [(37.1±2.4 ng/mL, 
p<0.001) and (39.2±3.0 ng/mL, p<0.001)], respectively. Moreover, in the 6,000 IU 
group, there was a significant decrease in serum 25(OH)D levels from 3 months 
(43.0±2.7 ng/mL) to 6 months (39.2±3.0 ng/mL, p=0.046) (Table 4).  
 
Hypothesis 2: Vitamin D3 supplementation at 6,000 IU/d will be more effective in 
increasing eGFR using CKD-EPI creatinine when compared to 4,000 IU/d over 6 
months. 
 
Unadjusted linear mixed models showed that the effect of time on CKD-EPI 
creatinine was statistically significant (p<0.001), intervention effect was 
marginally significant (p=0.067); however, the interaction between time and 
intervention was not statistically significant (p=0.110). Post-hoc LSD analyses 
showed that there was a marginally significant increase in CKD-EPI creatinine 
values from baseline (84.6±2.8 mL/min) to 3 months (88.0±2.9 mL/min, p=0.077) 
and significant increase in CKD-EPI creatinine values to 6 months (92.5±2.9 
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mL/min, p<0.001) in the 4,000 IU/d group. Moreover, significant increase was 
found from 3 months to 6 months (p=0.004) in the 4,000 IU/d group. In the 6,000 
IU/d group, marginally significant increase in mean CKD-EPI creatinine were 
observed from baseline (94.2±3.6 mL/min) to 6 months (97.9±3.7 mL/min, 
p=0.082).  
 
Adjusted linear mixed models indicated that the effect of time (p<0.001) on 
CKD-EPI creatinine was statistically significant. However, the intervention effect 
(p=0.0162) and the interaction effect of time and intervention were not statistically 
significant (p=0.121). Post-hoc analysis showed marginally significant increase in 
CKD-EPI creatinine values from baseline (83.8±3.2 mL/min) to 3 months 
(88.0±3.0 mL/min, p=0.074) and statistically significant increase to 6 months 
(93.0±3.1 mL/min, p<0.001) in the 4,000 IU/d group. Moreover, significant 
improvements in CKD-EPI creatinine values were also observed from 3 months 
(88.0±3.0 mL/min) to 6 months (93.0±3.1 mL/min, p=0.002) in the 4,000 IU/d 
group. Marginally significant increase in mean CKD-EPI creatinine values from 
baseline (90.1±3.9 mL/min) to 6 months (96.0±3.9 mL/min, p=0.059) were found 
in the 6,000 IU/d group (Table 5). 
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Table 5. Unadjusted and Adjusted Intervention Groups Comparisons of CKD-EPI creatinine at Different Time 
Points 
 Intervention 
 4,000 IU/d 6,000 IU/d 
Unadjusted n=39 n=24 
CKD-EPI creatinine (mL/min) Mean±SE 
   Baseline 84.6±2.8 94.2±3.6 
   3 months       88.0±2.9*; ** 97.7±3.7 
   6 months  92.5±2.9* 97.9±3.7 
P-value time<0.001 P-value intervention=0.067 P-value interaction=0.110 
Adjusted    
CKD-EPI creatinine (mL/min) Mean±SE 
   Baseline 83.8±3.2 91.0±3.9 
   3 months       88.0±3.0*; ** 96.0±3.8 
   6 months   93.0±3.2* 96.0±3.9 
P-value time<0.001 P-value intervention=0.162 P-value interaction=0.095 
Abbreviations: BMI= body mass index; 25(OH)D=25-hydroxy vitamin D; A1c=glycated hemoglobin; CKD-EPI=Chronic 
Kidney Disease Epidemiology Collaboration; SE=standard error. *Represents significant differences from baseline; 
**represents significant differences from 3 to 6 months.  
Adjustment variables: BMI, known years with diabetes, A1c, diabetes medications, blood pressure medications, 25(OH)D, 
vitamin D intake, sun exposure. Data reported as Mean±SE. P is considered significant at <0.05. 
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Hypothesis 3: Vitamin D3 supplementation at 6,000 IU/d will be more effective in 
increasing eGFR using CKD-EPI creatinine - cystatin C when compared to 4,000 
IU/d over 6 months. 
 
Unadjusted linear mixed models showed that the effect of time on CKD-EPI 
creatinine - cystatin C was statistically significant (p<0.011). However, the 
effect of intervention (p=0.105) or the interaction between time and intervention 
(p=0.636) were not statistically significant. LSD post-hoc analyses showed a 
significant decrease in CKD-EPI creatinine - cystatin C values from baseline 
(104.9±3.4 mL/min) to 6 months (97.6±3.2 mL/min, p=0.029) and from 3 months 
(106.7±3.5 mL/min) to 6 months (97.6±3.2 mL/min, p=0.002) in the 4,000 IU/d 
group. Additionally, changes in CKD-EPI creatinine - cystatin C values between 
intervention groups (4,000 IU/d vs. 6,000 IU/d) at 6 months were observed at the 
marginal significance level (97.6±3.2 mL/min vs. 107.4±4.1 mL/min, p=0.066) 
(Table 6). 
 
Adjusted linear mixed models indicated that the effect of time on CKD-EPI 
creatinine - cystatin C values were statistically significant (p=0.020). However, 
the effect of intervention (p=0.289) and time and intervention interaction 
(p=0.740) were not statistically significant. LSD post-hoc analyses showed a 
significant decrease in CKD-EPI creatinine - cystatin C values from 3 months 
(109.2±3.9 mL/min) to 6 months (100.9±3.7 mL/min, p=0.006) in the 4,000 IU/d 
group.   
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Table 6. Unadjusted and Adjusted Intervention Groups Comparisons of CKD-EPI creatinine - cystatin C at 
Different Time Points 
 Intervention 
 4,000 IU/d 6,000 IU/d 
Unadjusted n=39 n=24 
CKD-EPI creatinine - cystatin C 
(mL/min) 
Mean±SE 
   Baseline 104.9±3.4 112.6±4.3 
   3 months    106.7±3.5** 112.2±4.5 
   6 months    97.6±3.2* 107.4±4.1 
P-value time=0.011 P-value intervention=0.105 P-value interaction=0.636 
Adjusted    
CKD-EPI creatinine-cystatin C 
(mL/min) 
Mean±SE 
   Baseline 106.0±4.3 110.4±4.9 
   3 months    109.2±3.9** 112.4±4.7 
   6 months 100.9±3.7 107.1±4.3 
P-value time=0.020 P-value intervention=0.289 P-value interaction=0.830 
Abbreviations: BMI= body mass index; 25(OH)D=25-hydroxy vitamin D; A1c=glycated hemoglobin; CKD-EPI=Chronic 
Kidney Disease Epidemiology Collaboration; SE=standard error. *Represents significant differences from baseline; 
**represents significant differences from 3 to 6 months.  
Adjustment variables: BMI, known years with diabetes, A1c, diabetes medications, blood pressure medications, 
25(OH)D, vitamin D intake, sun exposure. Data reported as Mean±SE. P is considered significant at <0.05. 
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Hypothesis 4: Vitamin D3 supplementation at 6,000 IU/d will be more effective 
than the 4,000 IU/d over 6 months in lowering microalbuminuria measured by 
first morning urine samples.  
 
Unadjusted and Adjusted linear mixed models showed that the effect of 
time [(p=0.889) and (p=0.954)], intervention [(p=0.254) and (p=0.425)] and the 
interaction between time and intervention [(p=0.370 and (p=0.435)] on 
microalbuminuria were not statistically significant within and between 4,000 
IU/d and 6,000 IU/d groups, respectively (Table 7).  
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Table 7. Unadjusted and Adjusted Intervention Groups Comparisons of Microalbuminuria at Different Time 
Points 
 Intervention 
 4,000 IU/d 6,000 IU/d 
Unadjusted  n=39 n=24 
MAU (mg/dL) Mean±SE 
   Baseline 4.5±2.4 6.8±3.0 
   3 months 3.1±1.9 8.1±2.5 
   6 months 3.5±1.8 7.0±2.3 
P-value time=0.889 P-value intervention=0.254 P-value interaction=0.370 
Adjusted   
MAU (mg/dL) Mean±SE 
   Baseline 4.5±2.9 5.9±3.5 
   3 months 3.5±2.3 7.5±2.8 
   6 months 3.9±2.2 6.7±2.5 
P-value time=0.954  P-value intervention=0.425 P-value interaction=0.435 
Abbreviations: BMI= body mass index; 25(OH)D=25-hydroxy vitamin D; A1c=glycated hemoglobin; MAU=microalbuminuria; 
SE=standard error.  
Adjustment variables: age gender, BMI, known years with diabetes, A1c, diabetes medications, blood pressure medications, 
25(OH)D, vitamin D intake, sun exposure. Data reported as Mean±SE. P is considered significant at <0.05.       
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Aim 2: To evaluate the effect of vitamin D3 supplementation at 6,000 IU/d vs. 
4,000 IU/d on markers of cardiovascular disease risk among Hispanics and 
African Americans with type 2 diabetes and hypovitaminosis D (<30 ng/ml). 
 
Hypothesis 1: Vitamin D3 supplementation at 6,000 IU/d will be more effective 
than the 4,000 IU/d over 6 months in lowering systolic and diastolic blood 
pressure levels.  
 
Unadjusted mixed models showed marginally significant effect of time 
(p=0.080) and significant effect of intervention (p=0.001) on systolic blood 
pressure. A significant effect of the interaction between time and intervention 
(p=0.032) was observed. LSD post-hoc analyses indicated that systolic blood 
pressure levels significantly decreased from baseline (146.2±4.0 mmHg) to 3 
months (139.8±3.3 mmHg, p=0.035) and significantly higher decrease at 6 
months (135.0±3.5 mmHg, p=0.003) only in the 6,000 IU/d vitamin D group. 
Additionally, significant differences were observed in systolic blood pressure 
levels between 4,000 IU/d and 6,000 IU/d groups at 3 months [(126.5±2.6 mmHg 
vs. 139.8±3.3 mmHg, p=0.002)] (Table 8).  
 
Adjusted linear mixed models showed no significant effect of time on 
systolic blood pressure (p=0.490). However, the effect of intervention 
(p=0.006) and the interaction between time and intervention (p=0.026) were 
statistically significant. Post-hoc LSD analyses showed a significant decreased in 
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mean systolic blood pressure levels from baseline (144.1±4.0 mmHg) to 6 
months (134.5±3.5 mmHg, p=0.020) only for the 6,000 IU/d group. Furthermore, 
a marginal decrease in systolic blood pressure levels were observed in the 6,000 
IU/d group from 3 months (139.9±3.4 mmHg) to 6 months (134.5±3.5 mmHg, 
p=0.088). Significant differences between intervention groups (4,000 IU/d vs. 
6,000 IU/d) in systolic blood pressure levels were found at 3 months (128.5±2.6 
mmHg vs. 139.9±3.4 mmHg, p=0.007) but not in 6 months (Table 8).  
 
Unadjusted mixed models indicated that the effect of intervention on 
diastolic blood pressure was statistically significant (p=0.003). However, the 
effect of time (p=0.538) or the interaction between time and intervention 
(p=0.110) were not statically significant. LSD post-hoc analyses indicated that 
changes in diastolic blood pressure levels were marginally significant from 
baseline (91.8±2.2 mmHg) to 6 months (87.9±2.0 mmHg, p=0.055) in the 6,000 
IU/d group. Additionally, significant differences in mean diastolic blood pressure 
levels were observed at 3 months (83.2±1.5 mmHg vs. 89.3±1.9 mmHg, 
p=0.015) and marginally significant at 6 months (83.5±1.5 mmHg vs. 87.9±2.0 
mmHg, p=0.086) (Table 8).  
 
Adjusted linear mixed models analysis showed that the effect of 
intervention on diastolic blood pressure was statistically significant (p=0.004); 
however, the effect of time (p=0.703) or the interaction of between time and 
intervention (p=0.108) were not significant. Post-hoc LSD analyses revealed 
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marginally significant decrease in mean diastolic blood pressure levels from 
baseline values (91.3±2.6 mmHg) to 6 months (87.3±2.2 mmHg, p=0.086) only 
for the 6,000 IU/d group. Significant differences between intervention groups 
(4,000 IU/d vs. 6,000 IU/d) in diastolic blood pressure levels were observed at 3 
months (82.7±1.9 mmHg vs. 88.7±2.2 mmHg, p=0.017) (Table 8). 
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Table 8. Unadjusted and Adjusted Intervention Groups Comparisons of Blood Pressure at Different Time 
Points 
 Intervention 
 4,000 IU/d 6,000 IU/d 
Unadjusted n=39 n=24 
Systolic blood pressure (mmHg) Mean±SE 
   Baseline 126.8±3.1 146.2±4.0 
   3 months  126.5±2.6†  139.8±3.3* 
   6 months 127.9±2.7  135.0±3.5* 
P-value time=0.080 P-value intervention=0.001 P-value interaction=0.032 
Diastolic blood pressure (mmHg)   
   Baseline 82.3±1.7 91.8±2.2 
   3 months  83.2±1.5†  89.3±1.9 
   6 months 83.5±1.5  87.9±2.0 
P-value time=0.538 P-value intervention=0.003 P-value interaction=0.110 
Adjusted   
Systolic blood pressure (mmHg) Mean±SE 
   Baseline 127.1±3.3 144.1±4.0 
   3 months 128.5±2.6† 139.9±3.4 
   6 months 130.3±2.8   134.5±3.5* 
P-value time=0.490 P-value intervention=0.006 P-value interaction=0.026 
Diastolic blood pressure (mmHg)   
   Baseline 81.7±2.2 91.3±2.6 
   3 months  82.7±1.9† 88.7±2.2 
   6 months 82.9±1.9 87.3±2.2 
P-value time=0.703 P-value intervention=0.004 P-value interaction=0.108 
Abbreviations: BMI= body mass index; 25(OH)D=25-hydroxy vitamin D; A1c=glycated hemoglobin; SE=standard error. 
*Represents significant differences from baseline; † represents significant differences at 3 months between intervention 
groups.  Adjustment variables: age gender, BMI, known years with diabetes, A1c, diabetes medications, blood pressure 
medications, 25(OH)D, vitamin D intake, sun exposure. Data reported as Mean±SE. P is considered significant at <0.050.       
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CHAPTER IV: DISCUSSION 
Serum 25-hydroxy vitamin D 
The study focused on vitamin D3 supplementation interventions for Hispanics 
and Blacks with hypovitaminosis D and type 2 diabetes. All participants in our 
study had 25(OH)D levels below 30 ng/mL at baseline. Our findings showed that 
vitamin D3 supplementation noticeably increased 25(OH)D levels in both 
intervention groups which indicated that the supplement doses were adequately 
bioavailable, well absorbed and tolerated by the participants. It was expected that 
serum 25(OH)D levels would improve at 6 months in both groups; however, we 
found no significant differences between the 4,000 IU/d and 6,000 IU/d groups at 
the end of the study. Despite the high doses of vitamin D3 used in this study, 
there were no adverse events or signs of toxicity reported by any of the 
participants throughout the study.    
 
Several previous studies are available where vitamin D3 (cholecalciferol) was 
used to replenish serum 25(OH)D levels. Kim et al. (2011), used 
supplementation with vitamin D3 for participants with serum vitamin D deficiency 
(≤ 16 ng/ml) with 40,000 IU/week for 8 weeks and 40,000 IU/month for additional 
8 weeks; and participants with vitamin D insufficiency (16-32 ng/mL) with 40,000 
IU/month. They found significantly increased mean serum 25(OH)D levels from 
baseline (15.6±7.0 ng/mL) to 4 months (39.7±12.8 ng/ml) in individuals with type 
2 diabetes. In our study, mean 25(OH)D levels at baseline were 20.7 ng/mL for 
the 4,000 IU/d group and 21.7 ng/mL for the 6,000 IU/d. By the end of the 
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intervention (6 months), mean 25(OH)D levels increased to sufficient levels 37.9 
ng/mL for the 4,000 IU/d group and 38.9 ng/mL for the 6,000 IU/d group. In 
another study, individuals were supplemented with the equivalent of 10,000 IU/d 
for 3 months, mean 25(OH)D levels significantly increased (pre-intervention = 
13.4 ng/mL to post-intervention = 82.8 ng/mL). Conversely, there are studies 
where vitamin D3 supplementation did not replenish serum 25(OH)D levels above 
(30 ng/mL). These studies used doses of vitamin D3 supplementation ≤ 1000 IU/d 
or the equivalent (Oksa et al., 2008 and Rucker et al., 2009).    
 
The Institute of Medicine (IOM) guidelines (Institute of Medicine, 2011) 
specified that the Recommended Dietary Allowance (RDA) for >97.5% of the 
population for vitamin D intake is 600-800 IU/d. In our study, none of the 
participants met the RDA for vitamin D for their age, the mean vitamin D intake 
was 127.0±82.7 IU for the 4,000 IU/d group and 122.2±86.4 IU for the 6,000 IU/d 
group (Table 1).  Nevertheless, greater dosages than the RDA of vitamin D 
intake are needed it to replenish those with deficient and insufficient 25(OH)D 
levels. We investigated the effect of vitamin D3 supplementation using the IOM 
(Institute of Medicine, 2011) recommended tolerable upper intake level (4,000 
IU/d) and a higher dose (6,000 IU/d); however, the IOM recommendations for 
vitamin D are not formulated for those with preexisting conditions (such as 
diabetes). The Endocrine Society Clinical Practice Guideline advise that 
individuals with 25(OH)D levels below 20 ng/mL be supplemented with vitamin D3 
(6,000 IU/d) for eight weeks to restore normal vitamin D levels above 30 ng/mL. 
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After reaching sufficiency, vitamin D3 supplementation needs to be continued by 
a maintenance phase of 1,500-2,000 IU/d. Due to the high prevalence of vitamin 
D deficiency/insufficiency in individuals with type 2 diabetes, achieving normal 
25(OH)D levels should be considered an important therapeutic goal. The amount 
of vitamin D3 necessary to achieve adequate serum 25(OH)D levels for 
populations with multiple chronic conditions has yet to be established and may 
be confounded by variations in geographic region, seasons, skin color, sun 
exposure, race/ethnicity, diet, and body fat. The optimal 25(OH)D level that 
would have a clinical effect on health risk outcomes remains to be defined.  
 
Our study did not include a placebo or control arm, since the intervention 
groups were not recruited and conducted in parallel and due to the inclusion 
criterion, we included individuals with 25(OH)D levels with 
deficiency/insufficiency (<30 ng/mL). Ethically it was not appropriate or advisable 
to treat vitamin D deficient/insufficient participants with placebo for 6 months. 
Participants were not allowed to take any type or form of vitamin D supplement 
other than a multivitamin, and we encouraged them to not change their dietary 
and sun exposure habits during the study. The high doses of vitamin D3 used in 
this study were not only intended to replenish serum 25(OH)D levels but also to 
improve study outcomes (kidney and cardiovascular disease markers).  
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Glomerular Filtration Rate (GFR) 
Studies showed that diabetes and kidney disease are associated with low 
25(OH)D levels (Husemoen et al., 2012; Levin et al., 2007). Existing data 
indicate the relationship between hypovitaminosis D and mortality in individuals 
with chronic kidney disease (CKD) (Navaneethan et al., 2011). CKD is a 
predictor of vitamin D insufficiency/deficiency because the kidney is involved in 
the metabolism of vitamin D (Echida et al., 2012).  Findings from our study 
suggest the possible beneficial role of vitamin D3 supplementation on kidney 
function biomarkers in individuals with type 2 diabetes. Our study showed that 
individuals with type 2 diabetes had significantly improved kidney function by 
increasing CKD-EPI creatinine equation over time (pre-intervention = 84.6±18.4 
mL/min – post-intervention = 92.4±18.9 mL/min) in the 4,000 IU/d group and 
(pre-intervention = 94.2±17.5 mL/min to post-intervention = 97.9±18.0 mL/min) in 
the 6,000 IU/d group. The effect of vitamin D3 supplementation on markers of 
kidney function persisted after adjusting for major confounding variables only on 
the 4,000 IU/d group. This could be due to small number of participants in the 
6,000 IU/d group (n=24) and higher CKD-EPI creatinine values at baseline as 
compared to the 4,000 IU/d.  On the other hand, CKD-EPI creatinine - cystatin C 
equation indicated significant decrease over time (pre-intervention = 112.6±21.5 
mL/min to post-intervention = 98.6±24.0 mL/min) in the 4,000 IU/d group. There 
are several possible explanations for the different results from the eGFR 
equations. The study by Fan et al. (2014) compared the effectiveness of eGFR 
equations: CKD-EPI creatinine and CKD-EPI creatinine - cystatin C. Results 
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showed that CKD-EPI creatinine equation underestimated more individuals with 
elevated BMI as compared to the CKD-EPI creatinine - cystatin C equation. The 
CKD-EPI creatinine - cystatin C equation was more precise than CKD-EPI 
creatinine while estimating GFR values for those with diabetes and obesity. 
However, the study by Fan et al. (2014) have limitations. Pooled analyzed data 
from that study cannot distinguish between individuals with type 1 or type 2 
diabetes, the approaches used to estimate glomerular filtration rate, or factors 
that affected creatinine values.  
 
In a longitudinal study with a follow-up of over 4 years (n=1705) (De Boer et 
at., 2011), lower 25(OH)D levels were linked a faster change in eGFR rate loss 
among older adults, especially for those with 25(OH)D level below 15 ng/mL, 
diabetes and hypertension. Vitamin D3 supplementation (666 IU/d) for 6 months 
did not significantly change in eGFR values in either the intervention or control 
group and non-significant differences were found between study groups with 
CKD stages 3-4 (Molina et al., 2014). Vitamin D3 supplementation of 1000 IU/d 
versus a control for Canadian adults with later stages (3-5) of kidney disease 
study found no improvements in kidney function (GFR and albuminuria). 
Negative findings could be due to the mean 25(OH)D levels post-intervention 
being below the 30 ng/mL sufficiency and short duration of the supplementation 
(3 months) (Rucker et al., 2009). Two additional studies by Kim et al. (2011) and 
Basturk et al. (2011) found no significant changes in eGFR after vitamin D3 
supplementation. All the studies reported included participants in the later stages 
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of CKD 3-5 contrary to our study where we included participants with early 
stages of CKD (1-3). Early supplementation with vitamin D3 might provide a more 
valuable treatment and possibly delaying adverse kidney disease outcomes.  
  
 The National Kidney Foundation clinical guidelines indicated that individuals 
with CKD stages 3-4 and serum 25(OH)D levels (<30 ng/mL) to be treated with 
vitamin D2 instead of vitamin D3 (National Kidney Foundation, 2003). At the time 
(year 2003) when this guideline was written no controlled clinical studies were 
available comparing the safety and efficacy of vitamin D2 versus vitamin D3. 
Additionally, access to commercial high doses up to 50,000 IU are available for 
vitamin D2 (Houghton and Vieth, 2006). The dosage recommendation by the 
National Kidney Foundation clinical guidelines is according to the vitamin D 
status. Individuals with vitamin D deficiency [serum 25(OH)D levels (<5 ng/mL 
and 5-15 ng/mL)] should receive 50,000 IU/week for 4-12 weeks and then same 
dose monthly for 6 months. Individuals with vitamin D insufficiency [serum 
25(OH)D levels 16-30 ng/mL)] should receive 50,000 IU/month for 6 months 
(National Kidney Foundation, 2003). Nevertheless, previous studies 
demonstrated that supplementation with vitamin D2 were less consistent in 
reaching ideal serum 25(OH)D levels (> 30mg/mL) as compared to vitamin D3 
(Houghton and Vieth, 2006; Armas et al., 2004; Heaney et al., 2011). Several 
studies found a reduction in kidney disease markers using vitamin D analogues 
(paricalcitol) (Alborzi et al., 2008; de Zeeuw et al., 2010; Fishbane et al., 2009); 
however, vitamin D3 has been shown to be equally effective. The equal 
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effectiveness of vitamin D3 may be of importance since hypercalcemia has been 
observed with some vitamin D analogues (Moe et al, 2009). Vitamin D analogues 
are biologically active and individuals using them need to be monitored for 
hypercalcemia and hyperphosphatemia more closely than with vitamin D3 
(Kandula et al., 2011). There are no formal recommendations for vitamin D3 
supplementation for individuals with early CKD by the National Kidney 
Foundation. Still clarification and a more precise definition needs to be 
implemented for the vitamin D3 supplementation dosage, frequency, serum 
25(OH)D levels before intervention starts, and whether complications from kidney 
dysfunction can be prevented. Therefore, available guidelines from Kidney 
Disease Outcomes Quality Initiative (KDOQI) needs to be revised.   
 
Current study contributes to the scientific knowledge for understanding of the 
role of vitamin D3 supplementation on kidney function among minority groups. 
Early interventions could delay progression of the disease which would have a 
profound effect on lowering health care costs and burden to society as well as 
improving the quality of life (Jungers, 2002). Medical costs were doubled for 
individuals with kidney disease from a large Health Maintenance Organization 
(HMO) as compared to those without kidney disease (Smith et al., 2004). 
Therefore, approaches to manage kidney disease such as vitamin D3 
supplementation are important in clinical practice.   
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Microalbuminuria 
Reduction of urinary albumin levels is an important therapeutic goal that slow 
the progression of kidney dysfunction. Previous studies indicated that 
microalbuminuria was associated with cardiovascular disease and mortality in 
individuals with type 2 diabetes (Mogensen, 1984; Valmadrid et al., 2000). 
Microalbuminuria, abnormal increase in urinary albumin excretion, is an early 
sign of kidney dysfunction (Mogensen, 1984). In a prospective population-based 
study, individuals with type 2 diabetes (n=1,253) were followed for 7 years, 
microalbuminuria was linked to a 42% increase in the progression to 
nephropathy (Bruno et al., 2003). The usual course of microalbuminuria is 
progressive in individuals with type 2 diabetes (Bruno et al., 2003); therefore, 
early screening and treatment of microalbuminuria can reduce the risk for kidney 
dysfunction and possibly decrease the burden associated with diabetes 
complications.  
 
Several studies found an inverse association between 25(OH)D levels and 
albuminuria (de Boer et al., 2007; Skaaby et al., 2013; Isakova et al., 2011). Data 
from NHANES III that included (n=15,068) participants, found an inverse 
association between 25(OH)D levels and prevalence of albuminuria (de Boer et 
al., 2007). Furthermore, after excluding participants with macroalbuminuria from 
the statistical analysis, significant similar results were also found for 
microalbuminuria (de Boer et al., 2007). In a five-year follow-up study of a 
random sample of Caucasians (n=4,330), aged 30-60 years, low 25(OH)D levels 
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predicted higher urinary protein excretion (Skaaby et al., 2013). Hypovitaminosis 
D frequently occurs in minorities groups, especially in those with type 2 diabetes 
and kidney dysfunction. The clinical implications of monitoring microalbuminuria 
and 25(OH)D levels among individuals with type 2 diabetes may delay future 
adverse complications, especially among individuals with other concomitant 
conditions (i.e. hypertension).  
 
In our study, microalbuminuria did not improve over time by either dose of 
vitamin D3 supplementation. The findings from several studies corroborate our 
study results. In a randomized, double blind, clinical trial, fifty-two individuals 
[hemodialysis treated (n=27)/ non-hemodialysis treated (n=25)] with serum 
25(OH)D levels <20 ng/mL received vitamin D3 supplementation (40,000 
IU/week) or placebo. After 8 weeks, vitamin D3 supplementation did not 
significantly change urinary protein excretion (Marckmann et al., 2012). Urinary 
protein excretion showed no significant improvements in a Brazilian cohort 
(n=45) with CKD stages 3-4 that were supplemented with vitamin D3 (50,000 
IU/week) for 6 months (Garcia-Lopes et al., 2012). In contrast, several studies 
described that vitamin D3 supplementation reduce albuminuria. In a prospective 
study, individuals (n=63) with type 2 diabetes and CKD stages 2-4 were given 
vitamin D3 supplementation according to their serum vitamin D status. Results 
showed a reduction of albuminuria for those receiving vitamin D3 
supplementation (Kim et al., 2011). In the study by Molina et al. (2014), 
Caucasian older adult participants (n=101) with advance CKD (stages 3-4) 
                                                      
54 
 
received either vitamin D3 supplementation (666 IU/d) or placebo for 6 months. 
Urinary albumin-to-creatinine ratio significantly decreased only in participants 
who received vitamin D3 supplementation. Improving kidney function in 
individuals with type 2 diabetes play a vital role in preventing cardiovascular 
disease and development of end-stage renal disease (ESRD). 
 
Blood Pressure 
This study demonstrated that vitamin D3 supplementation improved systolic 
blood pressure in the higher dose group (6,000 IU/d). Our study found a 
reduction in systolic blood pressure of approximately 11 mmHg (pre-intervention= 
146.2±22.1 mmHg – post-intervention= 135.0±17.8 mmHg) by the end of the 6 
months’ intervention. Results of this study are consistent with some previous 
studies. A randomized, double-blind, clinical trial investigated the effect oral 
vitamin D3 cholecalciferol (50,0000 IU/per week) on blood pressure among 
individuals with type 2 diabetes (n=30 intervention/ n=30 placebo). Thirty-two 
participants in the study had either serum 25(OH)D levels classified as deficient 
(n=5) or insufficient (n=27). Vitamin D3 supplementation (50,000 IU per week) 
reduced systolic and diastolic blood pressure from baseline (121.0±13.0 mmHg 
and 80.5±8.0 mmHg) to 12 weeks’ follow-up (110.0±9.0 mmHg, p=0.001 and 
76.3±7.0 mmHg, p=0.046 respectively), only in the intervention group (Nasri et 
al., 2014). The efficacy of 8 weeks of vitamin D3 (800 IU/d) and calcium 
supplementation (1200 mg) vs. calcium supplementation (1200 mg/d) on blood 
pressure was measured on elderly women (n=148) with 25(OH)D levels below 
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(20 ng/mL). A significant reduction in systolic blood pressure of 9.3% 
[(baseline=144.1±20.4 mmHg) and (8-week follow-up=131.0±16.9 mmHg)] was 
found in the intervention with vitamin D3 and calcium group as compared to 
calcium alone group [(baseline=140.6±14.7 mmHg) and (8-week follow-up= 
134.9±19.9 mmHg)]; however, no significant decrease in diastolic blood pressure 
was found (Pfeifer et al., 2001). Another study (Sugden et al., 2008) investigated 
the effect of vitamin D2 (100,000 single oral dose) supplementation vs. placebo 
on blood pressure in individuals with type 2 diabetes and low 25(OH)D (<20 
ng/mL). After 8-week follow-up, participants in the vitamin D2 group (n=17) had 
reduced systolic blood pressure by 14 mmHg compared to those in the placebo 
group (n=17); however, no significant changes were found for diastolic blood 
pressure.  
 
In contrast, results from other studies found no improvements in blood 
pressure after vitamin D3 supplementation. Findings from the DAYLIGHT trial, a 
double-blind, randomized controlled study, which included (n=534) participants 
with age range of 18-50 years old, 25(OH)D levels (≤ 25 ng/ml), and 
prehypertension and/or untreated stage 1 hypertension indicated no beneficial 
effect of vitamin D3 supplementation groups (400 IU/d or 4,000 IU/d) on systolic 
or diastolic blood pressure after 6 months of intervention (Arora et al., 2014). This 
study is one of the largest sampled (46% Whites, 48% Blacks and 6% other 
ethnicity) clinical trial conducted were the primary endpoint was blood pressure. 
In a randomized controlled, double-blind clinical trial, vitamin D3 supplementation 
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(a single oral dose of 100,000 IU) did not significantly reduce blood pressure 
during the 5-week duration in elderly adults during winter (n=95 intervention 
group, n=94 placebo group) (Scragg et al., 1995). Vitamin D3 supplementation 
(Schleithoff et al., 2006) (intervention group, n=42, 2000 IU + Calcium 500 mg/d) 
or (placebo group, n=51, placebo + 500 mg calcium/d) did not change systolic or 
diastolic blood pressure after 9 months’ intervention in individuals with congestive 
heart failure. In the Women’s Health Initiative Randomized Trial (Margolis et al., 
2008), postmenopausal women (n= 36 282) were given vitamin D3 (400 IU/d) + 
calcium (1000 mg/d) or placebo. After a median of 7-year follow-up, there were 
no significant differences between the intervention and placebo groups in systolic 
or diastolic blood pressure. A randomized double-blind clinical trial with 1-year 
duration (Zittermann et al., 2009), provided vitamin D3 (3320 IU/d - 5 drops of oily 
vitamin D) or placebo (5 drops of vitamin D-free oil) to n=200 healthy overweight 
individuals with mean 25(OH)D levels of 12ng/mL (n=100 each group). Results 
from this study showed no significant time and intervention interaction effects for 
systolic or diastolic blood pressure. Jorde et al. (2010) conducted double-blind 
clinical randomized clinical trial including 438 overweight or obese participants 
using two dosages of vitamin D3 and placebo. One vitamin D3 group received 
40,000 IU/week, the second vitamin D3 group received 20,000 IU/week and the 
third group received placebo. Additionally, all vitamin D3 groups and placebo 
received 500 mg of calcium/d. After 1-year of intervention, findings do not 
support the efficacy of vitamin D3 supplementation in reducing blood pressure.  
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Inconsistent findings from these clinical trials could be due to: 1) studies were 
conducted and/or analyzed using different ranges of vitamin D supplementation 
alone or combined with calcium; 2) age range and gender of the participants; 3) 
duration of the studies; 4) comorbidities and ethnic background of the 
participants and 5) covariates included in the statistical analyses (Pittas et al., 
2010; Witham et al., 2009; Jorde et al., 2010; Beveridge et al., 2015; Larsen et 
al., 2012; Witham et al., 2010; Forman et al., 2013; Pfeifer et al., 2001; Sugden 
et al., 2008; Margolis et al. 2008). In our study, significant differences in blood 
pressure at baseline between vitamin D3 supplementation groups (4,000 IU vs. 
6,000 IU/d) could have make the interpretation of findings complex. The 6,000 
IU/d vitamin D3 group started with significantly higher levels of systolic and 
diastolic blood pressure as compared to the 4,000 IU/d group. On the other hand, 
the 4,000 IU/d had a higher percentage of participants on hypertension 
medications at baseline. We cannot dismiss that hypertensive medications might 
have contributed to the decrease in blood pressure levels in either intervention 
group. Nevertheless, throughout the duration of the study any medication change 
by the participants were recorded and adjustment for medications were taken 
into consideration in the statistical analysis. Those in the 4,000 IU/d group might 
benefited less from vitamin D3 supplementation because they had well-treated 
blood pressure levels.   
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The mechanism on how vitamin D affects blood pressure is poorly 
understood. Nonetheless, it has been postulated that vitamin D could affect blood 
pressure by regulating through the renin-angiotensin-aldosterone (RAAS) system 
(Li et al., 2004; Pilz et al., 2009). Our study did not include RAAS as an outcome 
measurement.  
 
Despite the high prevalence of both vitamin D deficiency/insufficiency and 
hypertension among our minority population groups, there are no efforts to 
establish preventive measures that could benefit individuals by screening for 
25(OH)D levels and providing vitamin D3 supplementation. These results ought to 
encourage researches to further examine the clinical significance and 
implications of vitamin D3 supplementation on elevated blood pressure levels that 
could have benefits for individuals with type 2 diabetes. Because evidence is still 
inconclusive, our findings support the potential therapeutic role of vitamin D3 
supplementation as complementary treatment for blood pressure; however, more 
rigorous clinical trials with larger sample sizes are required before recommending 
vitamin D3 supplementation exclusively to treat hypertension.  
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CHAPTER V: SUMMARY AND CONCLUSIONS 
Vitamin D deficiency/insufficiency is still a public health concern particularly 
affecting minorities with type 2 diabetes; therefore, more public health awareness 
is required to prevent consequences of vitamin D deficiency/insufficiency by 
identifying potential risk factors and develop effective interventions. This clinical 
trial sought to clarify the effect of vitamin D3 supplementation on kidney function 
and cardiovascular disease markers which goes beyond the prevention of bone 
health. The study included a sample of Hispanics and African Americans with 
type 2 diabetes and hypovitaminosis D who were given two high dosages of 
vitamin D3 supplementation (4,000 IU/d and 6,000 IU/d). Although, we found 
significant changes in kidney and cardiovascular disease markers, 
supplementation with vitamin D3 longer than 6 months may be needed to 
determine sustained long term effects in kidney and cardiovascular disease 
markers. Vitamin D3 supplements are relatively inexpensive and safe and can be 
used as adjunct treatment option to improve kidney function and decrease blood 
pressure and consequent cardiovascular disease. Individuals with type 2 
diabetes and kidney dysfunction and high blood pressure could benefit from 
vitamin D3 supplementation, especially those with low levels of serum 25(OH)D 
levels. Clinical recommendations should contain screening and monitoring of 
serum 25(OH)D levels: including the measurement of serum 25(OH)D as a 
routine assay for high risk populations to provide health care professionals with 
the information required to recommend and treat, as well as offering the 
appropriate resources as preventive health benefits. 
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Our results have set the foundations for further examination of the 
mechanisms and metabolic pathways associating vitamin D status with kidney 
and cardiovascular disease. Further research could provide more appropriate 
means for translation of these findings into recommendations for individuals with 
CKD, hypertension and type 2 diabetes. The efficacy of vitamin D3 
supplementation as complementary therapy for CKD and blood pressure in 
minority and other ethnic groups needs further investigation in larger and longer 
duration randomized controlled trials. 
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CHAPTER VI: STRENGTHS AND LIMITATIONS 
Strengths  
Major strengths of the study include: The study included two minority groups 
(Hispanics and Blacks) with high prevalence of serum 25(OH)D levels 
deficiency/insufficiency and type 2 diabetes. We tested the safety of vitamin D3 
supplementation at two high dose levels: 4,000 IU/d and 6,000 IU/d. Throughout 
the duration of the study, no adverse effects or signs of toxicity were observed 
[IOM tolerable upper limit intake (4,000 IU/d)] for 6 months. These two doses 
were safe and effective in increasing participant’s serum 25(OH)D levels in a 
population sample who started the study with hypovitaminosis D. We had a low 
number of drop-outs [(in the 4,000 IU/d group, n=1) and (in the 6,000 IU/d group, 
n=5)] and low non-compliance to the vitamin D3 supplementation [(in the 4,000 
IU/d group (n=3), and in the 6,000 IU/d group (n=2)]. We took in consideration 
several measurements and confounder variables that could affect the outcomes 
such as diet, sun exposure, body mass index (BMI), medications, years with 
diabetes where other studies were lacking. Our study recorded any medication 
change throughout the duration of the study and adjusted for that in the statistical 
analyses. We carefully selected the inclusion criteria to test our outcomes [(i.e. 
participants with serum 25(OH)D considered deficient and insufficient, CKD 
stages 1-3, etc.]. For the statistical analyses, we used linear mixed models since 
we had a longitudinal data with unbalanced number of participants in each study 
group (in the 4,000 IU/d group, n=39 and in the 6,000 IU/d group, n=24).   
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Limitations 
This study had several limitations. The study sample was a convenience 
sample and was not randomly selected from the general adult population in 
Miami-Dade County; therefore, results of this study cannot be generalized or 
extrapolated to the entire U.S. adult population nor Miami-Dade County. Non-
randomized groups could create selection bias because of the non-random 
assignment. The advantage of this convenience sample was its large minority 
representation; it was recruited from two clinics that have culturally diverse 
populations in Miami-Dade County. The relatively small sample size and greater 
numbers of female participants were other limitations of the study. Additionally, 
not having sufficient number of participants prevented the investigators to 
measure differences between ethnic groups (only few Black participants), and 
the uneven numbers of participants in each vitamin D3 supplementation group 
may have decreased the statistical power of the study. The study lacked a 
control group - changes observed in the pre- and post-test might be due not only 
to the supplementation with vitamin D3, but to other factors such as change in the 
diet, sun exposure, or vitamin D supplements; however, we assessed for 
changes in these parameters during the study. We did not assess which 
mechanisms underlining vitamin D3 function were acting in kidney disease or 
blood pressure and how they were affected or changed by supplementation. 
Although trained interviewers who were bilingual in English and Spanish were 
present to administer the questionnaires to assess dietary habits of vitamin D, 
participants might under- or overestimated their intakes. There was more than 
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50% of participants in each vitamin D3 supplementation group taking 
hypertension medications, which possibly influenced blood pressure outcome 
over time; however, changes in medications were recorded and medication 
usage was used as a control variable in the analysis. Additionally, we advised 
participants to keep their medication use constant during the duration of the 
study, as prescribed by their primary physician. Lastly, conclusions beyond the 6 
months’ supplementation could not be drawn to understand the impact of long 
term effects of vitamin D3 supplementation. Studies with longer duration of 
supplementation and follow-up maybe needed to see these effects of vitamin D3 
supplementation in this sample or other ethnic groups. 
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CHAPTER VII: FUTURE RESEARCH 
It will be important to comprehend the role and impact of high levels of 
vitamin D3 supplementation in larger cohorts with different geographical and 
ethnic backgrounds. Additionally, it will be important to examine longitudinal 
trajectories of kidney and cardiovascular disease markers, especially in high risk 
populations with existing comorbidities. Further evidence will allow for a greater 
understanding of the influence of changes in serum 25(OH)D values on kidney 
function, cardiovascular disease markers and type 2 diabetes. Investigation of 
these mechanisms and metabolic pathways are critical for developing effective 
interventions for the translation of findings into recommendations for care among 
individuals with type 2 diabetes. As the source for future research, findings from 
this study may have public and clinical health implications that could contribute to 
the expansion of ethnic-tailored interventions to reduce health disparities and 
prevent the high incidence of these chronic diseases in minorities.  
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Appendix 2: Short Food Frequency Questionnaire 
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Appendix 3: Skin Color and Anthropometrics Control Form 
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